中国医学前沿杂志（电子版）2025，Vol.17Issue(4)：7-11,5.DOI:10.12037/YXQY.2025.04-02
早期乳腺癌辅助强化治疗策略
The new strategies and future prospects for adjuvant intensified therapy in early-stage breast cancer
摘要
Abstract
Adjuvant intensified therapy is increasingly demonstrating its critical role in the treatment of early-stage breast cancer,particularly for patients at high risk of recurrence and those who fail to achieve pathological complete response after neoadjuvant therapy.This strategy aims to further reduce the risk of disease recurrence and improve cure rates by extending treatment duration,introducing new agents,or employing multiple therapeutic approaches.In recent years,intensified treatment regimens for triple-negative breast cancer,hormone receptor-positive breast cancer,and human epidermal growth factor receptor 2-positive breast cancer—such as capecitabine,cyclin-dependent kinase 4/6 inhibitors,and dual-targeted therapy—have shown promising clinical efficacy with manageable safety.Additionally,the use of poly(ADP-ribose)polymerase inhibitors in breast cancer patients with genetic susceptibility mutations has yielded encouraging results.In the future,with continuous optimization of therapeutic strategies,adjuvant intensified therapy is expected to bring even greater benefits to patients with early-stage breast cancer.This article will review the adjuvant intensive treatment strategies for different molecular subtypes of early-stage breast cancer,such as triple-negative breast cancer,hormone receptor-positive breast cancer,human epidermal growth factor receptor 2-positive breast cancer,and other special types of breast cancer,with the aim of contributing to the clinical treatment of early-stage breast cancer.关键词
乳腺癌/早期/辅助强化治疗/不同分子分型Key words
Breast cancer/Early-stage/Intensified therapy/Different molecular subtypes引用本文复制引用
黎立喜,刘姝宁,李巧佴,李凤娟,马飞..早期乳腺癌辅助强化治疗策略[J].中国医学前沿杂志（电子版）,2025,17(4):7-11,5.基金项目
National Key Research and Development Program of China(2021YFF1201300)国家重点研发计划(2021YFF1201300) （2021YFF1201300）
